Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $2.65 USD
Change Today -0.05 / -1.85%
Volume 7.1K
ERB On Other Exchanges
Symbol
Exchange
NYSE Amex
As of 8:04 PM 05/1/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

14100 NW 57th Court

Miami Lakes, FL 33014

United States

Phone: 305-324-2300

Fax:

ERBA Diagnostics, Inc., through its subsidiaries, develops, manufactures, and markets diagnostic test kits, or assays, and automated systems that are used to aid in the detection of disease markers primarily in the areas of autoimmune, infectious diseases, clinical chemistry, hematology, and diabetes testing. The company is a subsidiary of ERBA Diagnostics Mannheim GmbH. The company’s subsidiaries include Delta Biologicals, S.r.l. (Delta); Diamedix Corporation; Drew Scientific, Inc.; ImmunoVision, Inc.; and JAS Diagnostics, Inc. The company’s tests are designed to aid in the identification of the causes of illness and disease, assist physicians in selecting appropriate patient treatment. Its tests are based on various technologies, including Enzyme Linked ImmunoSorbent Assay (ELISA) technology, clinical chemistry, hematology, and cell separation, as well as HPLC separations, all of which are clinical testing methodologies used worldwide. The company’s kits are designed to be performed either manually or in an automated format. In addition to its line of diagnostic kits, the company designs and manufactures laboratory instruments that perform the tests and provides results. Its existing proprietary instruments, named the Mago 4, Mago 4S, Mago Plus, and Aptus systems, include an automated ELISA processor operating with its own software, which allows customers to perform tests in an automated mode. The company updated the Mago Plus instrument to include the capability to process ELISA and ImmunoFluorescent Assay (IFA) simultaneously. It also delivers an upgraded version of the Mago Plus instrument, named the Mago 4, which performs both ELISA and IFA techniques simultaneously, performs positive sample identification, and utilizes disposable pipette tips. The Mago 4 offers an improved automation solution to customers who prefer a lower-priced instrument. The company also continued the development of a variation of the Mago Plus, named the Mago 4S, for the market in the United States. The Mago 4S also performs both ELISA and IFA techniques simultaneously. The company received the required 510(k) regulatory clearance for the Mago 4S and markets the instrument in the United States. The company also develops, manufactures, and markets raw materials, such as antigens used in the production of diagnostic kits. Sales and Marketing The company markets its products in the United States primarily through its own sales force to hospitals, reference laboratories, clinical laboratories, and research laboratories, as well as to other commercial companies that manufacture diagnostic products. It distributes its products in the United States through certain independent distributors. The company also sells some of its products to pharmaceutical and biotechnology companies. The company markets its products in certain international markets through a network of independent distributors. It markets and sells its products in Italy through Delta’s sales representatives and independent agents, who are restricted from selling competing products. The company also sells its products in other global markets through various independent distributors. Its marketing and technical service departments located in Miami Lakes, Florida, Springdale, Arkansas, and Pomezia, Italy support their efforts. The products that the company markets in the United States are purchased principally by healthcare providers that bill third party payors, such as governmental programs (Medicare and Medicaid), private insurance plans, and managed care plans, for healthcare services provided to their patients. In Italy and various other countries in Western Europe, the company’s products are sold primarily to public hospital laboratories, which are managed by government structures, either directly or indirectly. Research and Development The company incurred $840,000 for research and development activities in 2013. Its research and development efforts have been targeted primarily towards the development of the next-generation instrument — LISA XL. Governmental Regulation The testing, manufacturing, and selling of the company’s products are subject to regulation by various governmental authorities, principally the United States Food and Drug Administration. Competition The company’s competitors include Bio-Rad Laboratories, DiaSorin, INOVA, Alere, Meridian Bioscience, The Binding Site, and others. History ERBA Diagnostics, Inc. was founded in 1980.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ERB:US $2.65 USD -0.05

ERB Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Alere Inc $48.60 USD +1.12
Bio-Rad Laboratories Inc $134.96 USD +0.51
DiaSorin SpA €40.72 EUR -0.73
Meridian Bioscience Inc $17.69 USD -0.03
View Industry Companies
 

Industry Analysis

ERB

Industry Average

Valuation ERB Industry Range
Price/Earnings 100.0x
Price/Sales 4.1x
Price/Book 6.3x
Price/Cash Flow 80.4x
TEV/Sales 4.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ERBA DIAGNOSTICS INC, please visit www.erbadiagnostics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.